Nifedipina Sandoz (Nifedipine)

Nifedipine blocks L‑type calcium channels in vascular smooth muscle and cardiac cells, preventing calcium entry during depolarisation. This inhibition causes arterial relaxation, reduces peripheral resistance, and lowers myocardial oxygen demand, which together lower blood pressure and alleviate anginal pain.

The appropriate dose of Nifedipina Sandoz is determined by the prescribing healthcare professional based on the individual’s condition, response, and other medical factors. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety data for nifedipine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss risks with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nifedipine is a dihydropyridine‑type calcium‑channel blocker, primarily causing arterial vasodilation. Compared with other agents such as amlodipine, nifedipine has a shorter half‑life and may require more frequent dosing, but both share similar efficacy for hypertension and angina. Choice often depends on patient tolerance, dosing convenience, and physician preference.

Store Nifedipina Sandoz at room temperature, below 25 °C, in the original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

Nifedipina Sandoz is taken orally. The tablet should be swallowed whole with a glass of water, preferably at the same times each day as directed by the prescriber. It can be taken with or without food, unless otherwise advised.

Serious risks include severe hypotension, which can cause fainting or shock, myocardial infarction especially in patients with existing coronary disease, and rare but life‑threatening allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience sudden weakness, chest pain, or signs of an allergic response.

Nifedipina Sandoz should be avoided in individuals with known hypersensitivity to nifedipine or other calcium‑channel blockers, those with severe hypotension, cardiogenic shock, or recent myocardial infarction. Caution is also advised for patients with severe aortic stenosis or uncontrolled heart failure.